Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ
Completed · Phase 1/Phase 2
Conditions studied: Breast Cancer
In brief
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen or letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the body makes. PURPOSE: This clinical trial is studying how well tamoxifen or letrozole work in treating women with ductal carcinoma in situ.
Key facts
- Study ID
- NCT00290745
- Run by
- University of California, San Francisco
- People needed
- 79
- Starts
- 2002-02-19
- Expected to finish
- 2011-06-30
- Last updated by the study team
- 2020-12-04
Who can join
Age: any. Sex: female. Healthy volunteers: not accepted.
Where it is running
- University of California, San Francisco — San Francisco, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.